Original from  Mindray Website

August 25, Mindray (300760.SZ) announced financial results for the first half ended June 30, 2021.

The first-half sales of CNY 12.778 billion increased 20.96% year-on-year. The net earnings attributable to common stockholders was CNY 4.344 billion, increasing 25.79% than the same period in the last year.

As one of the leading global providers of medical devices and solutions, Mindray’s innovations cover a broad spectrum of medical industry, including patient monitoring and life support, in-vitro diagnostics and medical imaging system. Patient monitoring and life support sales increased 12.68% in the first half, achieving CNY 6.021 billion. In-vitro diagnostics sales increased about 30%, achieving CNY 3.962 billion in the first half of 2021. Medical imaging system sales CNY 2.671 billion with an increase of 26.87% in the first half of 2021.

Mindray is committed to consistent investment in R&D, a guarantee of our continuous innovation. In the first half of 2021, Mindray invested CNY 1.165 billion in R&D, growing 16.02% year-on-year.

On May 16, Mindray announced that it intends to acquire 100% of the equity of Hytest Invest Oy in Finland and its subsidiaries through its wholly-owned subsidiary MR Global (HK) Limited and Mindray Medical Netherlands BV. Through this acquisition, Mindray will strengthen its developing capability in core raw material, ensure supply safety and optimize the operating costs.

Mindray’s 39 subsidiaries and over 10,000 employees are serving over 190 countries and regions around the world. Mindray is now recognized by their strong performance with increasing global impact.